Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Capecitabine for First Line Treatment of Recurrent/Metastatic SCCHN
NCT00216138Phase 2Terminated
- Sponsor
- Hoosier Cancer Research Network
- Start
- Mar 2004
- Primary completion
- Sep 2007
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and capecitabine in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Hoosier Cancer Research Network. Primary endpoint: Objective Response Rate at 24 months. Started Mar 2004; status: terminated.
02
Drugs
docetaxelcapecitabine
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00216138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00216138.